Article
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Liver international : official journal of the International Association for the Study of the Liver - 1 Nov 2016
Kowdley Kris V, Nelson David R, Lalezari Jacob P, Box Terry, Gitlin Norman, Poleynard Gary, Rabinovitz Mordechai, Ravendhran Natarajan, Sheikh Aasim M, Siddique Asma, Bhore Rafia, Noviello Stephanie, Rana Khurram
Abstract excerpt
BACKGROUND AND AIMS: Many currently available direct-acting antiviral (DAA) regimens are less effective against HCV genotype 3 than against other HCV genotypes. The all-oral, pangenotypic DAA combination of daclatasvir (NS5A inhibitor) + sofosbuvir (nucleotide NS5B inhibitor) was studied in genotype 3-infected treatment-naive and -experienced patients (ALLY-3) who achieved rates of sustained virological response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.